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Abstract: Background: Various human cardiovascular pathophysiological conditions associate aberrant 
expression of microRNAs (miRNAs) and circulating miRNAs are emerging as promising biomarkers. In 
mice, myocardial miR-21 overexpression is related to cardiac fibrosis elicited by pressure overload. 
This study was designed to determine the role of myocardial and plasmatic miR-21 in the maladaptive 
remodeling of the extracellular matrix induced by pressure overload in aortic stenosis (AS) patients 
and the clinical value of miR-21 as a biomarker for pathological myocardial fibrosis. 
Methods: In left ventricular biopsies from 75 AS patients and 32 surgical controls, we quantified the 
myocardial transcript levels of miR-21, miR-21-targets and ECM- and TGF-β-signaling-related 
elements. miR-21 plasma levels were determined in 25 healthy volunteers and in AS patients. In situ 
hybridization of miR-21 wasperformed in myocardial sections.  
Results: The myocardial and plasma levels of miR-21 were significantly higher in the AS patients 
compared with controls and correlated directly with the echocardiographic mean transvalvular 
gradients. miR-21 overexpression was confined to interstitial cells and absent in cardiomyocytes. 
Using bootstrap validated multiple linear regression, the variance in myocardial collagen expression 
was predicted by myocardial miR-21 (70% of collagen variance) or plasma miR-21 (52% of collagen 
variance), together with the miR-21 targets RECK and PDCD4, and effectors of TGF-β signaling.  
Conclusions: Our results support the role of miR-21 as a regulator of the fibrotic process that occurs in 
response to pressure overload in AS patients and underscore the value of circulating miR-21 as a 
biomarker for myocardial fibrosis. 
 
 




Dear Dr Coats, 
 
We are herewith submitting the manuscript entitled “Myocardial and 
circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis 
patients” to be considered for publication in the International Journal of Cardiology. 
The results of our study evidence that both myocardial and circulating levels of miR-21 
reflect in human patients with aortic stenosis the process of extracellular matrix 
remodeling in the left ventricle. The study cohort is, to our knowledge, the largest ever 
published of prospectively collected aortic stenosis patients in whom the availability of 
left ventricular biopsies, harvested at valvular surgery, allowed the study of myocardial 
gene expression together with other clinical, imaging or serological variables. Our 
findings provide new mechanistic insights and reinforce the value of the plasma levels 
of this mi-RNA, possibly in conjunction with other biomarkers, in the clinical 
assessment of a phenomenon of utmost prognostic repercussion as myocardial fibrosis 
is. 
Statistical advisorship was performed by Prof. Javier Llorca (Professor of 
Statistics and Epidemiology) from our university. The manuscript has been edited by 
qualified native English speaking editors at American Journal Experts. 
All authors have read and agree to the manuscript as written. The manuscript is 
not under consideration elsewhere and none of the paper's contents have been published 
previously. The authors maintain no conflict of interest. 
 




J. Francisco Nistal, MD, PhD 
Cardiovascular Surgery 
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Dear Prof. Coats, 
 I am pleased to send you the revised version of our manuscript “Myocardial and 
circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis 
patients” (Ref. No.:  IJC-D-12-00582). The manuscript was modified according to 
your instructions and the criticisms of the reviewer have been addressed, as 
outlined below in detail. We hope that you will find the revised version suitable for 
publication in the International Journal of Cardiology. 
Reviewers' comments: 
 
1. Is miR-21 the only miRNA regulated? What about other miRNAs involved in 
fibrosis such as miR-29? 
Authors' answer:  
In a preliminary set of PCR experiments we studied the regulation by the pressure 
overload condition of several miRNAs selected on the basis of their involvement in 
myocardial remodeling or their relationship with TGF-beta signaling pathways. 
miR-133a, miR-21 and miR-29 arose as those miRNAs which featured the greatest 
changes in mice subjected to aortic banding and in aortic stenosis patients. miR-
133a is associated in humans with aortic stenosis with a lesser degree of LV 
hypertrophy preoperatively and a better reverse remodeling after aortic valve 
replacement, but it does not predict fibrosis severity prior to or after surgery (Villar 
et al. Heart 2011). With regard to miR-29, we found that in the pressure overload 
*Detailed Response to Reviewers
condition it experiences a complex sex dependent regulation that we are currently 
analyzing in detail.      
 
2. Methods/microRNA expression: please correct: using specific primers for mi-
R21. 
Authors' answer:  
This point was addressed in page 9, line 4. 
 
3. miR-21 expression has been previously demonstrated by in situ hybridization; 
however, why is there such a big difference in RT-PCR data vs. miR-21 
hybridization signal?  
Authors' answer: 
Quantitative-PCR provides the average expression values of miR-21 in the whole 
biopsy sample while in situ hybridization shows the topographic distribution of miR-
21 hybridization signals which, in the AS patients, is concentrated in fibrotic areas. 
We selected for the figure a representative area of fibrotic tissue with intense 
accumulation of miR-21 to further support that this miRNA is expressed mostly by 
fibroblasts. Hence, both the PCR and in situ hybridization data are not necessarily 
incompatible.  
 
4. Please check pri-miR-21 expression in myocardium to see whether there are 
also transcriptional changes. 
Authors' answer: 
We included additional data showing that myocardial pri-miR-21 was also up-
regulated in the pressure overload condition, and that its expression correlated 
significantly with the expression of TGF-beta, which suggests that, in this context, 
the transcription of miR-21 is under the control of this cytokine (page 11, lines 9 to 
12; page 13, lines 13 to 16; and page 17, lines 4 to 6). 
 
Minor comments: 
The page numbers were added. 
The abbreviation list was corrected. 
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Background: Various human cardiovascular pathophysiological conditions associate 
aberrant expression of microRNAs (miRNAs) and circulating miRNAs are emerging as 
promising biomarkers. In mice, myocardial miR-21 overexpression is related to cardiac 
fibrosis elicited by pressure overload. This study was designed to determine the role of 
myocardial and plasmatic miR-21 in the maladaptive remodeling of the extracellular 
matrix induced by pressure overload in aortic stenosis (AS) patients and the clinical 
value of miR-21 as a biomarker for pathological myocardial fibrosis. 
Methods: In left ventricular biopsies from 75 AS patients and 32 surgical controls, we 
quantified the myocardial transcript levels of miR-21, miR-21-targets and ECM- and 
TGF-β-signaling-related elements. miR-21 plasma levels were determined in 25 healthy 
volunteers and in AS patients. In situ hybridization of miR-21 was performed in 
myocardial sections.  
Results: The myocardial and plasma levels of miR-21 were significantly higher in the 
AS patients compared with controls and correlated directly with the echocardiographic 
mean transvalvular gradients. miR-21 overexpression was confined to interstitial cells 
and absent in cardiomyocytes. Using bootstrap validated multiple linear regression, the 
variance in myocardial collagen expression was predicted by myocardial miR-21 (70% 
of collagen variance) or plasma miR-21 (52% of collagen variance), together with the 
miR-21 targets RECK and PDCD4, and effectors of TGF-ß signaling.  
Conclusions: Our results support the role of miR-21 as a regulator of the fibrotic 
process that occurs in response to pressure overload in AS patients and underscore the 




Key words: aortic stenosis, myocardial fibrosis, microRNA, plasma miR-21, TGF-ß 
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Non-standard Abbreviations and Acronyms 
AS: aortic stenosis 
Col: collagen 
ECM: extracellular matrix  
FN: fibronectin 1  
LV: left ventricle  
miRNA: microRNA 
PDCD4: programmed cell death 4  
PTEN: phosphatase and tensin homolog  
RECK: reversion-inducing-cysteine-rich protein with kazal motifs 
SPRY1: sprouty homolog 1  
TAK-1: TGF-β activated kinase-1 
TIMP3: tissue inhibitor of metalloproteinase 3  









Degenerative aortic stenosis (AS) has become the most frequent type of valvular 
disease in industrialized countries (2–7% of the population older than 65 years) and its 
incidence is rising in parallel to the increasing life expectancy [1]. Surgical aortic valve 
replacement is the only therapy with confirmed survival benefit, and at present, no 
medical therapy can delay the inevitability of surgery. Older age is associated with a 
higher frequency of comorbidity, which contributes to increased operative risk and 
renders decision-making for intervention more complex [2]. Under pathological pressure 
loading, such as AS, the left ventricle (LV) experiences a remodeling process that is 
characterized by the hypertrophic growth of cardiomyocytes and the increased 
deposition of extracellular matrix (ECM) elements [3]. The development of diffuse, 
reactive myocardial fibrosis is a major cause of abnormal myocardial stiffness [4] which 
results in systolic and/or diastolic dysfunction that is proportional to the degree of ECM 
deposition [5-8]. The extent of myocardial fibrosis, which may not be reversible after 
delayed surgery, has important prognostic implications, because it is an independent 
predictor of perioperative mortality [9] and a key determinant of long-term functional 
outcome following aortic valve replacement [5,10,11]. 
MicroRNAs (miRNAs) are non-coding small RNAs that modulate the expression 
of target genes by repressing translation and/or inducing mRNA degradation. The 
aberrant expression of miRNAs is associated with multiple pathological processes, 
including processes that affect the cardiovascular system [12-15].  To date, few studies 
have analyzed the differential expression profiling of miRNAs in failing human hearts of 
different etiologies in comparison with control patients [16-18]. The distinctive pattern of 
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miRNA expression changes between heart diseases has led to the suggestion that 
miRNAs may have etiological implications and that their expression profiles could be 
useful as potential biomarkers for diagnosing patients and predicting the prognosis and 
response to therapy [19]. One particular miRNA that is consistently deregulated under 
various cardiovascular pathological conditions is miR-21 [20]. Through loss-of-function 
and gain-of-function approaches, a key regulatory role for miR-21 has been evidenced 
in the pathological remodeling of the myocardium induced by hemodynamic stress [21-
23]. The up-regulation of miR-21 in response to cardiac injury protects fibroblasts 
against apoptosis, which results in LV interstitial fibrosis and hemodynamic dysfunction 
[22]. The relationship of miR-21 up-regulation with the remodeling of ECM has also been 
demonstrated in mouse models of ischemia/reperfusion and acute myocardial infarction 
[24-26]. miR-21 was postulated to repress the transcription of myocardial mRNA targets 
including sprouty homolog 1 (SPRY1) [22], phosphatase and tensin homolog (PTEN) 
[23] and programmed cell death 4 (PDCD4) [27,28]. In addition, some miR-21 targets 
validated in extracardiac tissues [29], such as reversion-inducing-cysteine-rich protein 
with kazal motifs (RECK) and the tissue inhibitor of metalloproteinase 3 (TIMP3), play 
key roles in the control of the ECM homeostasis [30,31] which deserve further attention 
in the scenario of human pressure overload. 
Transforming growth factor-β1 (TGF-β1) is a crucial player in the LV remodeling 
response to hemodynamic stress [3] both in rodent models [32,33] and in AS patients 
[5,8,34]. The involvement of miR-21 in the molecular mechanism underlying the effects 
of TGF-β1 has become a key focus of recent research. Smads, which are the canonical 
effectors of TGF-β signaling, regulate the transcription of primary miR-21 and its post-
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transcriptional processing by the DROSHA complex [35]. In TGF-β-dependent events, 
miR-21 is closely linked to the abnormal an excessive deposition of ECM [20,36], and 
several reports determined that miR-21 acts downstream of TGF-β to modulate the 
genesis and progression of pathological fibrotic processes in the liver [37], kidneys 
[38,39] and lungs [40]. Overall, these findings led us to hypothesize that miR-21 could 
be an actor in the pressure overload-induced ECM remodeling process dependent on 
TGF-β signaling in AS patients. 
Recent reports indicate the presence of circulating miRNAs in microvesicles or 
protein–miRNA-complexes that can be consistently quantified in human plasma and 
other body fluids [41]. Several studies reported altered plasma levels of various miRNAs 
in cardiovascular diseases [42], including acute myocardial infarction, stable coronary 
artery disease, acute and chronic heart failure and myocarditis [43]. Therefore, the 
altered circulating levels of selected miRNAs may reflect specific cardiovascular 
pathologies and could be useful biomarkers for cardiovascular diseases. However, there 
are no data available on the possible function of circulating/extracellular miRNAs as 
endocrine/paracrine signaling molecules that contribute to cardiovascular disease 
pathogenesis. 
Thus, the aim of this study was to investigate the following: (a) the role of both 
myocardial and plasmatic miR-21 in the maladaptive ECM remodeling induced by 
pressure overload in AS patients; (b) the association between validated miR-21 targets 
and TGF-β signaling effectors; and (c) the potential clinical value of miR-21 as a disease 





The authors of this manuscript have certified that they comply with the Principles 
of Ethical Publishing in the International Journal of Cardiology [44].  
Study populations 
The clinical and demographic characteristics of the AS and control groups are 
shown in Table 1. The study was performed using LV myocardial intraoperative biopsies 
and plasma samples obtained from a cohort of 75 consecutive patients diagnosed with 
isolated severe AS and undergoing aortic valve replacement surgery in the University 
Hospital Marqués de Valdecilla in Santander, Spain. Patients with aortic or mitral 
regurgitation greater than mild or with major coronary stenosis greater than 50%, 
previous cardiac operations, malignancies or poor renal or hepatic function were 
deemed ineligible for the study. The control group for comparing the myocardial gene 
expression was a cohort of 32 surgical patients with pathologies (atrial septal defect: 
n=20, aortic aneurysm: n=6, mitral stenosis: n=3, left atrial myxoma: n=2, pulmonary 
valve fibroelastoma: n=1) that did not include pressure or volume overload, coronary 
heart disease or cardiomyopathies. The reference values for the circulating miR-21 
plasma levels were obtained from a cohort of 25 healthy volunteers who were age-
matched with the AS patients and lacked previous cardiac disease. The study followed 
the Declaration of Helsinki guidelines for investigation in humans. The institutional ethics 
and clinical research committee of the University Hospital Valdecilla approved the study 




A two-dimensional transthoracic echocardiogram was performed (Philips-Hewlett 
Packard, IE 33) preoperatively. Images were digitalized and analyzed off-line (Xcelera 
software, Philips). Internal LV end-diastolic and end-systolic diameters (LVEDD and 
LVESD respectively) and interventricular septum thickness (IVST) and posterior wall 
thickness (PWT) were measured according to the American Society of 
Echocardiography guidelines, using bidimensional or M-mode images depending on the 
quality and angulation between the ultrasound beam and the LV. LV ejection fraction 
(LVEF) was calculated using Quiñones formula and LV mass (LVM) was estimated 
according to the Devereux formula and indexed to patient height in meters to the 2.7th 
power. Peak and mean transvalvular aortic gradients were obtained using the modified 
Bernoulli equation. 
Myocardial and plasma sampling 
Myocardial tru-cut needle subepicardial biopsies (4-10 mg) were collected from 
the lateral LV wall during surgery and were immediately either frozen in liquid nitrogen or 
fixed in paraformaldehyde. Peripheral venous blood samples were collected from 
healthy volunteers and AS patients; in the latter group, the samples were drawn 24 h 
preoperatively. To minimize platelet degranulation, the blood was drawn from an 
antecubital vein without tourniquet, using a syringe with a wide-gauge needle and the 
blood was then gently transferred to a collection tube containing EDTA. Within 15 
minutes of collection, the plasma was separated by centrifugation at 1000×g for 30 min; 
plasma aliquots were stored at -80°C until analysis. 




Total RNA was isolated from the LV using TRIzol (Invitrogen), according to the 
manufacturer’s protocol. The mRNA was reverse transcribed using random primers with 
an RT-PCR kit (Fermentas) and the tissue miRNAs were reversed transcribed using 
specific primers for miR-21 and RNU6B (TaqMan assays, Applied Biosystems). The 
cDNA products were amplified using quantitative PCR (q-PCR) and an MX-3000P 
Stratagene thermocycler using specific TaqMan assays (Applied Biosystems) for the 
following: (a) miR-21; (b) the remodeling-related genes TGF-β1, Smad2, Smad3, 
Smad4, TAK-1, collagen I α1 (Col I), collagen III α1 (Col III), fibronectin-1 (FN), and (c) 
the miR-21 target genes PTEN, PDCD4, RECK, TIMP3 and SPRY1.  
The expression levels of myocardial genes were normalized to the housekeeping 
gene, ribosomal 18S, which was measured in parallel for each sample e. The 
myocardial miR-21 expression was normalized to the endogenous control, RNU6B. No 
differences in the threshold cycles of RNU6B between the AS patients (27.1±0.8) and 
controls (27.3± 0.7) were found.  
Total RNA was isolated from the plasma samples using TRIzol. The isolation 
efficiency of the plasma miRNAs was assessed using spiked-in Caenorhabditis elegans 
miRNA (cel-miR-39) (Qiagen) lacking sequence homology to human miRNAs, as 
described previously [45]. The oligonucleotides were spiked into the samples during the 
RNA isolation after incubating the plasma with the denaturing solution. The plasma 
miRNAs were reverse transcribed using specific primers for mi-R21 and cel-miR-39 
(Applied Biosystems), and the plasma miR-21 levels were normalized to cel-miR-39. To 
assure that the isolation efficiency was homogeneous between the samples, the 
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extraction procedure was repeated, if necessary, until the cel-miR-39 cycle threshold fell 
within a range of 23.0±1.0.  
miR-21 in situ hybridization 
A digoxigenin (DIG)-double-labeled specific miR-21 probe (5´-DIG/TCA ACA TCA 
GTC TGA TAA GCT A/DIG-3´) and a scramble miRNA probe (5´-DIG/GTG TAA CAC 
GTC TAT ACG CCC A/DIG-3´) as a negative control were purchased from Exiqon 
(Vedbaek, Denmark). The procedure for the in situ hybridization was conducted in 
accordance with the manufacturer’s instruction using 4 μm sections of the 
paraformaldehyde-fixed, paraffin-embedded LV samples [46]. Digital photographs of the 
LV sections were captured using a camera (Axiocam MRc5, Zeiss) attached to a 
microscope (Leica DM IRB). 
Statistics 
The data sets were assessed for normality with the Kolmogorov-Smirnov test. 
Continuous variables were compared using two-tailed Student’s t-test when Gaussian 
and the Mann-Whitney U test when non-Gaussian. miR-21 was measurable in all 
patients and was treated as a continuous variable. Variables that were not normally 
distributed were transformed to their natural logarithm for the regression analyses. 
Correlations between the expression levels of miR-21 and cardiac remodeling genes 
were performed using Pearson’s correlation coefficient. Multiple linear regression 
analysis was used to identify the predictors of the myocardial collagen I expression 
variance. Independent variables introduced in the regression equation were assessed 
for multicollinearity and eliminated when appropriate. Models were validated using the 
bootstrap method with 2,000 replications. The threshold for statistical significance was 
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p<0.05. The following statistical packages were used: GraphPad Prism 5.03, PASW 




The preoperative echocardiographic, clinical and demographic data of the patient 
cohorts are shown in Table 1. Patient demographic and clinical characteristics were 
presented as means ± standard deviation. 
Myocardial and circulating levels of miR-21 were higher in the AS patients than in 
the control patients and correlated directly with the transvalvular gradients 
Patients with AS featured higher myocardial expression levels of  primary 
transcripts (pri-miR-21) as well as mature miR-21 (Fig 1A) compared with a group of 
surgical controls with no pressure or volume overload and normal left ventricular mass 
[pri-miR-21(surgical controls:  8.9±2.4 vs. AS:15.0±9.9; p<0.05 Mann-Whitney test);  
miR-21 (surgical controls: 45.3±5.7 vs. AS: 80.3±7.7; p<0.05 Mann-Whitney test)]. Since 
AS patients were significantly older than surgical controls (Table 1), we ruled out an 
influence of age on miR-21 expression by comparing subgroups of age-matched 
individuals from both cohorts (38 AS patients aged 63.0±10.5 years vs. 15 surgical 
controls aged 59.8±9.0 years). As shown in Fig 1B, the difference of miR-21 expression 
between the subgroups of age-matched patients was similar to the observed in the full 
cohorts.  
Using in situ hybridization (Fig 1 C), we detected intense miR-21 signals in the LV 
myocardium from the AS patients. The signal was restricted to the cells located in the 
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interstitial space, presumably fibroblasts, whereas no miR-21 signals were detected in 
the cardiomyocytes. In contrast, there was no miR-21signal or only a very weak 
hybridization signal in the LV myocardia from the control patients.  
The myocardial miR-21 expression levels displayed no significant differences 
related to sex (women: 92.2±12.7; men: 77.0±9.2), hypertension (normotensive: 
93.9±13.2; hypertensive: 75.7±8.9), obesity (BMI<30: 81.65±9.9; BMI>30: 73.6±7.8) and 
diabetes mellitus (non-diabetic: 87.4±9.4; diabetic: 73.4±10.6). The myocardial levels of 
miR-21 did not correlate significantly with the LV mass index (R=0.19), the body mass 
index (R=-0.08) or the age (R=-0.01).  
The circulating concentrations of miR-21 (Fig 1D) were significantly higher in the 
AS patients than in the age-matched healthy volunteers of similar demographic 
characteristics and also higher than in surgical controls [AS patients (20.1±3.7) vs. 
healthy individuals (3.9±0.6): p<0.01; and AS patients vs. surgical controls (8.8±1.8): 
p<0.05)]. The difference between healthy and surgical controls did not reach statistical 
significance. There was a direct and positive correlation between the myocardial 
expression and plasma levels of miR-21 (Fig 1E), suggesting that the myocardium is 
among the relevant sources that contribute to the circulating miR-21.  
Both, the myocardial and plasma levels of miR-21 maintained significant positive 
correlations with the mean transvalvular aortic gradients (Figs 1 F and G), which 
suggests a relationship between the level of the LV hemodynamic burden and miR-21 
up-regulation.  
Sex (women: 23.5±5.9; men: 17.8±4.8), hypertension (normotensive: 19.0±5.5; 
hypertensive: 20.4±5.2); obesity (BMI<30: 20.1±4.5; BMI>30: 23.4±7.7) and diabetes 
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mellitus (non-diabetic: 21.0±4.5; diabetic: 17.4±4.2) did not have a significant effect on 
the circulating miR-21 levels. LV mass index (R=0.01), body mass index (R=0.13) and 
age (R=-0.11) did not correlate significantly with the plasma levels of miR-21. 
Myocardial and circulating levels of miR-21 correlated positively with the 
myocardial expression levels of genes encoding ECM remodeling-related 
elements and TGF-β1  
The relative degree of myocardial fibrosis displayed by our cohort of AS patients 
was assessed by quantifying the LV expression levels of several ECM genes. The 
expression levels of collagen I, collagen III and fibronectin were significantly higher in 
the AS patients than in the surgical controls (Table 2). The myocardial and circulating 
levels of miR-21 were positively correlated with the LV myocardial expression levels of 
genes encoding collagen I and fibronectin (Table 3). The expression levels of genes 
encoding TGF-β1 and its effectors are shown in Table 2. The LV transcript levels of 
TGF-β1 (Table 3) sustained significant positive correlations with the myocardial 
expressions of both pri-miR-21 (R=0.69; p<0.01) and mature miR-21 (R=0.51; p<0.001), 
as well as with the plasma levels of miR-21 (R=0.50; p<0.001). 
Myocardial expression levels of miR-21 together with TGF-β effectors and miR-21 
target mRNAs predicted the variance of myocardial collagen I mRNA expression 
levels  
The bootstrap validated multiple linear regression analysis identified the 
myocardial expression levels of miR-21, Smad2 and TAK-1 as independent, 
significantly, positive predictors of collagen I expression variance. The resulting equation 
was the following: Collagen I = 0.08 + 0.014 (miR-21) + 0.87 (Smad2) + 1.21 (TAK-1). 
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The adjusted R2 (0.42; p<0.0001) indicated that the 42% of variance in myocardial 
collagen I can be predicted from this model. 
In a second step, we assessed whether introducing the myocardial expression 
levels of miR-21 targets, such as SPRY1, PTEN, TIMP3, RECK and PDCD4, in the 
regression model as independent variables would improve the prediction power of the 
equation. Table 2 shows the expression levels of the miR-21 targets in AS patients and 
surgical controls. As shown in Table 4, PDCD4 was a significant negative predictor of 
collagen I expression, whereas RECK, miR-21, Smad2 and TAK-1 appeared positively 
related to fibrosis [Collagen I = -0.41 + 0.02 (myocardial miR-21) + 8.73 (RECK) – 0.77 
(PCDC4) + 0.78 (Smad2) + 1.09 (TAK-1)]. The predictive strength of the resulting 
equation (adjusted R2: 0.70; p<0.0001) was clearly improved with these changes. In this 
model, myocardial miR-21 expression was the relatively largest contributor to collagen I 
variance, as indicated by its highest standardized beta coefficient (beta=0.58, Table 4).  
Circulating levels of miR-21 together with TGF-β effectors and miR-21 target 
mRNAs predicted the variance of myocardial collagen I mRNA expression levels  
We reproduced the same analysis substituting the miR-21 myocardial expression 
levels with the miR-21 plasma levels. The circulating miR-21, myocardial Smad2 and 
TAK-1 levels constituted significant positive predictors of the collagen I expression 
variance. The resulting equation (Collagen I = 0.33 + 0.019 (miR-21) + 0.79 (Smad2) + 
1.55 (TAK-1)] was similar to the one presented above but with a lower predictive 
strength (adjusted R2: 0.33; p<0.0001). 
Following the introduction of SPRY1, PTEN, TIMP3, RECK and PDCD4 
expressions as independent variables in the regression model (Table 5), PDCD4 still 
15 
 
constituted a significant negative predictor of collagen I expression and RECK, miR-21, 
and TAK-1 appeared positively related to fibrosis (Collagen I =-0.06 + 0.024 (plasma 
miR-21) + 9.80 (RECK) – 0.52 (PCDC4) + 1.57 (TAK-1)]. The inclusion of these two 
miR-21 targets still improved the predictive strength of the resulting equation (adjusted 
R2: 0.52; p<0.0001).  
Age, sex, body mass index, hypertension or diabetes mellitus did not improve the 
predictive power of the model and revealed no significant relationships with myocardial 
collagen I mRNA. 
Myocardial expression and circulating levels of miR-21 lacked of significant value 
for LV mass prediction  
There was no correlation between myocardial or plasma levels of miR-21 and LV 
mass or its related echocardiographic parameters. Further, multivariate analysis failed to 
find a significant value of miR-21, in combination with other clinical and gene expression 
parameters, to predict crude or indexed LV mass. 
 
Discussion 
Abundant evidence derived from basic research suggests a key role for several 
miRNAs, including miR-21, in the pathophysiology of many cardiovascular pathological 
processes. However, a direct assessment of their involvement in human heart diseases 
has rarely been addressed [19]. In the present study, which was performed in one of the 
largest series of intraoperative LV myocardial biopsies from AS patients, we provided 
evidence supporting a significant role for miR-21 in the pathological remodeling of the 
myocardium in the scenario of human aortic valve stenosis. We found that myocardial 
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expression of miR-21 was significantly higher in AS patients than in surgical controls, as 
previously reported in mice subjected to aortic arch constriction [22]. The miR-21 levels 
were proportional to the mean aortic transvalvular gradients; that is, to the degree of 
hemodynamic overload that the LV of the AS patients had to bear. This result suggests 
a link between the severity of the pathology and miR-21 up-regulation in the 
myocardium. Ikeda et al reported that miR-21 is not among the miRNAs whose 
expression is deregulated in the LV, as based on a cohort of 13 AS patients [47]. This 
divergent finding may be accounted for by differences in the area where the biopsies 
were harvested or by the different technologies used for the miRNA determination. 
Although, miR-21 null mice display no alterations in the LV remodeling responses 
to different stressors [48], several studies in rodent experimental models support a 
profibrotic effect mediated by miR-21 in the myocardium under pressure overload [21] 
and in other pathological conditions, including ischemia/reperfusion injury and acute 
myocardial infarction [24]. Herein, the miR-21 overexpression was confined to the 
interstitial cells within the ECM, which is in agreement with a predominant presence of 
miR-21 in the cardiac fibroblasts as described previously [22-24]. This topographic 
distribution and the positive correlation between the myocardial expression levels of 
miR-21 and the mRNAs that encode fibrillar proteins, such as collagen I and fibronectin, 
strongly support the hypothesis that miR-21 can act as an intracellular mediator with an 
active role in the maladaptive remodeling of the myocardial ECM that is triggered by 
pressure overload in AS patients.  
TGF-β is one of the most important promoters of the excessive and abnormal 
deposition of ECM proteins in the myocardium under biomechanical stress [3]. In a 
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previous report [8] and in the present study, the AS patients exhibited myocardial 
overexpression of TGF-β1, which was accompanied by a proportional up-regulation of 
fibrosis-related mRNAs. We observed that the myocardial transcript levels of TGF-β1 
also maintained positive relationships with the expression levels of pri-miR21 and 
mature miR-21, which agree with the regulatory roles of TGF-β signaling on miR-21 
transcription [20] and post-transcriptional maturation [35,49]. In addition, miR-21 is also 
critically involved in the mechanisms underlying the profibrogenic effect of TGF-β1: it 
regulates the TGF-β1-induced transdifferentiation of cultured fibroblasts into 
myofibroblasts [36], and the process of endothelial-to-mesenchymal transition, which is 
dependent on TGF-β1, both in vitro and in the pressure overloaded murine heart [23]. 
Furthermore, miR-21 contributes to the genesis and progression of fibrotic processes in 
animal models by acting downstream of TGF-β1 [37-40]. Our results showing a 
coordinated expression of miR-21 and the mRNAs encoding TGF-β1 and its signaling 
effectors in the myocardium of AS patients, strongly suggest that these molecules may 
constitute a cluster of functionally interacting elements whose expression is tightly 
coordinated to regulate the remodeling of the ECM under conditions of pressure 
overload. This idea is further supported by our multiple regression analysis which 
showed that the myocardial mRNA expression levels of Smad2 and TAK-1, together 
with miR-21 predicted 42% of the variance of the collagen I expression levels, whereas 
miR-21 alone predicted only 24%. 
In a further step, we assessed whether the expression of a series of miR-21 
target mRNAs (SPRY, PTEN, TIMP3, RECK and PDCD4) contributed to predicting 
myocardial fibrosis more than the set of variables composed of miR-21, Smad2 and 
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TAK-1. The inclusion of PDCD4 and RECK as independent variables in the multiple 
regression analysis led to a robust improvement in the predictive strength of the final 
model that accounted for 70% of the variance in the expression of collagen I. PDCD4 
constituted a negative predictor of collagen I expression, whereas RECK, miR-21, 
Smad2 and TAK-1 expression levels appeared to be positively related to fibrosis in the 
resulting equation. The repression of PDCD4 by miR-21 enhances the TGF-β1-
stimulated transdifferentiation of cultured fibroblasts into myofibroblasts [36]. In addition, 
the protective effect of miR-21 against ischemia-induced cardiac cell death is mediated, 
at least in part, by targeting PDCD4.27-29 In our study, the behavior of PDCD4 as a 
negative predictor of fibrosis and its inverse relationship with miR-21 indicate that it 
performed, as expected, as a miR-21 target involved in the remodeling of the ECM in AS 
patients. 
The membrane-anchored metalloproteinase (MMP) regulator RECK behaved as 
a positive predictor of collagen I expression in our multiple regression model. This result 
is in agreement with the reported profibrogenic effects exerted by RECK in pancreatic 
stellate cells [50]. Furthermore, in patients with atrial fibrillation, pathological atrial 
fibrosis is associated with increased levels of RECK and results in severe alterations in 
the turnover of collagens I and III [51]. Mutant mice lacking RECK display an elevated 
MMP activity that is accompanied by a greatly reduced amount of type I collagen and 
important defects in collagen fibrils [28]. RECK is a target of repression by miR-21 in 
cancer cells [29]. Herein, however, RECK did not behave as would be expected for a 
miR-21 target because, similar to miR-21, RECK positively predicted collagen 
expression, and its expression levels did not correlate inversely with miR-21.  
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In our study, the lack of predictive power of collagen I expression by SPRY, 
PTEN and TIMP3 suggests that these proteins are not involved in the 
pathophysiological imbalance between pro- and anti-fibrotic forces in severe human AS. 
Species-related differences and limitations in the adequacy of experimental models for 
the clinical diseases may account for the dissimilarities observed in the human scenario.  
The regulatory role of miR-21 in cardiomyocyte hypertrophy is a controversial 
matter at present. Whereas some studies find that miR-21 promotes the hypertrophic 
growth of cultured neonatal cardiomyocytes [21], others report that miR-21 represses 
the hypertrophic growth of myocytes [52]. Studies in vivo support that, under myocardial 
biomechanical stress such as pressure overload, the proliferation of fibroblasts, which 
are the major source of miR-21 in the heart, would be responsible for miR-21 
enrichment, fibrosis development and subsequent indirect effects on cardiomyocytes 
[22]. In our study, there was no correlation between the myocardial expression of miR-
21 and the LV mass. Further, multivariate analysis failed to find a significant value of 
miR-21, in combination with other clinical and gene expression parameters, to predict 
LV mass. Our results suggest a limited pathophysiological relevance of miR-21 in the 
development of myocardial hypertrophy under pressure overload in AS patients. On the 
other hand, we reported previously that myocardial miR-133a is negatively correlated 
with LV mass in the same cohort of AS patients, and its expression levels predict 
regression of LV hypertrophy after aortic valve replacement [15]. 
The preoperative circulating levels of miR-21 were higher in the AS patients when 
compared to cohorts of healthy individuals and surgical controls with pathologies that did 
not include pressure overload. The plasma levels of miR-21 directly correlated with the 
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myocardial expression levels of miR-21 and also maintained a direct linear relationship 
with the mean aortic transvalvular gradients. A remarkable observation is that 
myocardial fibrosis can be influenced by circulating miR-21, as suggested by the direct 
correlation between the preoperative plasma levels of miR-21 and the myocardial 
expression levels of collagen I and fibronectin. Furthermore, substitution of myocardial 
miR-21 mRNA levels by circulating miR-21 in the multiple regression analysis and 
inclusion of RECK, PDCD4 and TAK-1 led to a model that predicts 52% of the 
myocardial collagen I variance. The biological significance of circulating miRNAs is 
unclear, and to our knowledge, there is currently no evidence demonstrating a functional 
role for plasma miRNAs via distant gene modulation in humans. Our present results 
strongly suggest, for the first time, that circulating miR-21 may function as a paracrine 
signal to influence the remodeling of the myocardial ECM. The potential sources of miR-
21 in the plasma may be multiple because miR-21 is almost ubiquitously expressed; 
however, the direct correlation observed between the myocardial expression and 
plasma levels of miR-21 suggests that myocardial cells are among the relevant 
contributors to the levels of circulating miR-21. 
Specific signatures of circulating miRNAs may serve as novel biomarkers for 
diagnostic use and/or prognostic stratification [53]. Our results strongly suggest that the 
plasma levels of miR-21 could constitute a clinically relevant measurable characteristic 
of AS patients that provide information on the extent of myocardial fibrosis. Although 
miR-21 is not cardiac specific and its predictive strength on myocardial fibrosis-related 
gene expression is moderate, these facts do not exclude the use of miR-21 as a 
biomarker but suggest its use in conjunction with other clinical, echocardiographic or 
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serological markers to construct a myocardial fibrosis risk profile. Furthermore, the 
reliable assessment of the time progression of myocardial fibrosis using such a tool may 
add criteria for earlier valve replacement surgery, avoiding the dismal prognosis that is 
associated with severe fibrosis and help in the follow-up of changes promoted by 
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Figure 1. (A)  The relative expression level (RE) of miR-21 in the myocardium  
from AS patients was significantly higher than in surgical controls. (B) The 
myocardial overexpression of miR-21 in the subgroup of aged-matched patients 
(red symbols) was similar to the full cohort (black symbols). (C) miR-21 
expression (in situ hybridization using digoxigenin-labeled riboprobes). Compared 
with controls, the AS patients displaye strong overexpression of miR-21 that is 
localized in cells within the extracellular matrix. (D) The plasma levels of miR-21 
were higher in AS patients in comparisson with either surgical controls or age-
matched healthy volunteers. The circulating levels of miR-21 were not 
significantly different in the surgical controls than in the healthy volunteers (Mann-
Whitney test).  Linear regression analysis showed the  positive correlation 
between myocardial (E) and plasma (F) expression levels of miR-21 (log-
transformed) with the mean transvalvular gradients. (G) In AS patients, there was 
a positive correlation between LV myocardial and circulating expression levels of 
miR-21 (log-transformed). A and B: *p<0.05 vs. surgical controls. C: **p<0.01 vs. 












Number 75 32 25 
Age (yrs) 70.2±11.0* 53.6±15.5 70.8±7.1 
Male/Female (n) 42/33 10/23 12/13 
Systolic blood pressure, mm Hg 119.4±19.9 120.1±18.0 131.0±22.1 
Diastolic blood pressure, mm Hg 66.2±11.9 69.8±10.4 75.3±11.8 
LV mass index (g/m2.7) 77.0±19.8*** 39.8±14.0 49.7±14.5 
Posterior wall thiknesses (mm) 12.7±2.2*** 8.6±1.3 9.0±1.6 
LV ejection fraction 62.2±11.5 61.9±8.2 62.0±8.5 
Body Mass Index, kg/m2 28.9±4.1 28.2±4.9 27.4±3.3 
Body Mass Index ≥ 30, n (%) 25 (33) 10 (31) 5 (20) 
Systemic hypertension, n (%) 41 (55) 14 (44) 5 (20) 
Diabetes Mellitus, n (%) 17 (23) 2 (6) 0 (0) 
Atrial fibrillation or flutter, n (%) 13 (17) 4 (13) 1 (4) 
ACE inhibitors, n (%) 16 (21) 5 (16) 1 (4) 
AT-II receptor antagonists, n (%) 9 (12) 4 (13) 1 (4) 
Diuretics, n (%) 34 (45) 9 (28) 1 (4) 
Calcium antagonists, n (%) 12 (16) 3 (9) 2 (8) 
-Blockers, n (%) 11 (15) 10 (31) 3 (12) 
Statins, n (%) 23 (31) 2 (6) 6 (24) 
 
Patient demographic and clinical characteristics are presented as means ± standard 
deviation. *p<0.05, ***p<0.001 AS patients vs. surgical controls (Mann Whitney U test). 
ACE = Angiotensin converting enzyme; AT-II = Angiotensin II
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Table 2. Myocardial expression levels of genes encoding the extracellular matrix 
proteins collagen I, collagen III and fibronectin, TGF-β1 and its effectors Smad2, Smad3, 
Smad4 and TAK-1, and the mir-21 targets PTEN, TIMP3, PCDC4, SPRY1 and RECK. 
AS patients vs.  controls: *p<0.05, ***p<0.001 (Student’s t test or Mann Whitney U test). 
 
 Controls AS patients 
Collagen I 2.2±0.2 4.4±0.2*** 
Collagen III 5.4±0.4 7.0±0.6* 
Fibronectin 5.7±0.8 9.0±0.6* 
TGF-β1 1.7±0.1 2.4±0.1* 
Smad2 1.4±0.2 1.5±0.2 
Smad3 1.7±0.2 1.5±0.09 
Smad4 4.1±0.2 3.8±0.2 
TAK-1 1.2±0.01 1.3±0.02 
PTEN 1.7±0.1 1.3±0.1* 
TIMP3 4.7±0.3 3.4±0.1*** 
PCDC4 3.2±0.3 3.1±0.2 
SPRY1 0.04±0.002 0.03±0.004 





Table 3. Pearson's correlation coefficient values (R) obtained from the linear regression 
analyses correlating the myocardial and plasma levels of miR-21 with the myocardial 




 Col I FN TGF-β1 
Myocardial 
miR-21 
0. 49*** 0.53*** 0.51*** 
Plasma   
miR-21 





Table 4. Myocardial miR-21 is a significant predictor of the myocardial collagen I 
expression variance in the AS patients. A) Model calculated using bootstrap validated 
multiple linear regression analysis; B) goodness of fit and C) significant predictors of the 
myocardial expression levels of collagen I. 
 
A)  Collagen I = -0.41 + 0.02 (myocardial miR-21) + 8.73 (RECK) – 0.77 (PCDC4) + 
0.78 (Smad2) + 1.09 (TAK-1)  
 




Variable Coeff. B Std. Error Beta p value 
 Myocardial miR-21 0.02 0.003 0.58 <0.0001 
 RECK 8.73 1.42 0.55 <0.0001 
 PCDC4 -0.77 0.16 -0.45 <0.0001 
 Smad2 0.78 0.33 0.27 <0.02 




Table 5. Circulating miR-21 is a significant predictor of the myocardial collagen I 
expression variance in the AS patients. A) Model calculated using bootstrap validated 
multiple linear regression analysis; B) goodness of fit; and C) significant predictors of the 
myocardial expression levels of collagen I. 
 
A)  Collagen I =-0.06 + 0.024 (plasma miR-21) + 9.80 (RECK) – 0.52 (PCDC4) + 
1.57 (TAK-1)  
 






Variable Coeff. B Std. Error Beta p value 
 RECK 9.80 1.56 0.62 <0.0001 
 PCDC4 -0.52 0.19 -0.30 <0.008 
 TAK-1 1.57 0.53 0.33 <0.004 
 Plasma miR-21 0.024 0.008 0.27 <0.006 
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